Tivdak® (tisotumab vedotin-tftv) significantly prolonged overall survival in patients with recurrent or metastatic cervical cancer compared with chemotherapy in global phase 3 innovatv 301 trial

Media release tivdak demonstrated statistically significant overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at esmo 2023 congress results from innovatv 301 intended to serve as pivotal confirmatory trial for u.s. accelerated approval and to support global regulatory applications copenhagen, denmark, and bothell, wash.; october 22, 2023 – genmab a/s (nasdaq: gmab) and seagen inc. (nasdaq: sgen) announced additional results today from the phase 3 innovatv 301 randomized global trial, which showed treatment with tivdak demonstrated a statistically significant and clinically meaningful 30 percent reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, compared with chemotherapy (hr: 0.70, 95 percent ci: 0.54-0.89, p=0.0038i).
SGEN Ratings Summary
SGEN Quant Ranking